-
1رسالة جامعية
المؤلفون: Koenig, Alice
مرشدي الرسالة: Lyon, Thaunat, Olivier
مصطلحات موضوعية: Cellule Natural Killer, Rejet chronique, Missing-self, Transplantation, Inhibiteurs de mTOR, NK cell, Chronic rejection, MTOR inhibitors, 570
الوصف: La transplantation d'organe est le meilleur traitement en cas de défaillance terminale d'un organe vital. Cependant, la survie sur le long terme est limitée par la perte inexorable de la fonction des greffons. Cette dernière est attribuée à l'inflammation microvasculaire (1MV) causée par la réponse anticorps contre les alloantigènes (rejet humoral chronique (RHC)). En analysant une cohorte de 129 transplantés rénaux présentant de l'1MV sur une biopsie de greffon, nous avons trouvé que, dans la moitié des cas, les lésions n'étaient pas médiées par les anticorps. Chez ces patients, des études génétiques ont révélé une prévalence plus élevée de « mismatches » entre les molécules HLA de classe 1 (HLA-1) du donneur et les « Killer-cell immunoglobulin-receptors » (K1R) inhibiteurs des NK du receveur. Nous avons émis l'hypothèse que la nature allogénique de l'endothélium du greffon pouvait créer un « pseudo-missing-self ». De ce fait, les NK du receveur, exposés à des stimuli inflammatoires, ne reçoivent plus les signaux inhibiteurs transmis par le HLA-1 de la part des cellules endothéliales du donneur. Dans un modèle de co-culture de cellules endothéliales et de NK humains, nous avons démontré que l'absence d'un ligand HLA-1 du soi sur la cellule endothéliale peut activer les NK. Cette activation dépend de la voie mTOR dans les NK, qui peut être bloquée par la rapamycine, un inhibiteur de mTORC1 disponible en clinique. Enfin, nous avons confirmé l'existence de rejets NK induit par le « missing-self » et leur sensibilité à la rapamycine dans un modèle murin de transplantation cardiaque. Notre travail identifie un nouveau type de rejet chronique, exclusivement médié par l'immunité innée, les NK, ayant le même impact délétère sur la survie des greffons que le RHC. Cependant, alors qu'il n'y a pas de traitement disponible pour le RHC, les inhibiteurs de mTOR préviennent efficacement le développement de lésions dans un modèle murin de rejet vasculaire chronique induit par le « missing self »
Organ transplantation is the best treatment for terminal organ failure. However, long-term outcome of organ transplantation remains limited by inexorable loss of graft function, which the prevalent dogma links to the microvascular inflammation (MVI) triggered by the recipient's antibody response against alloantigens (antibody-mediated chronic rejection, AMR). Analysing a cohort of 129 renal transplant patients with MVI on graft biopsy, we found that, in half of the cases, histological lesions were not mediated by antibodies. In these patients, genetic studies revealed a higher prevalence of mismatches between donor HLA-I and inhibitory Killer-cell immunoglobulin-receptors (KIR) of recipient's NK cells. We hypothesized that the allogeneic nature of graft endothelium could create a "pseudo-missing self" situation, thereby the recipient's NK cells exposed to inflammatory stimuli would not receive HLA I-mediated inhibitory signals from donor endothelial cells. In co-culture experiments with human NK cells and endothelial cells, we demonstrated that the lack of self HLA-I on endothelial cells can activate NK. This activation triggers mTOR pathway in NK, which can be blocked by rapamycin, a commercially available inhibitor of mTORC1. Finally, we confirmed the existence of missing self-induced rejection and its sensitivity to mTOR inhibition in a murine heart transplantation model. Our work identifies a new type of chronic rejection, exclusively mediated by innate NK cells, with the same detrimental impact on graft survival as AMR. However, while no therapy is available for AMR, mTOR inhibitors efficiently prevent the development of lesions in murine models of NK cell-mediated chronic vascular rejection -
2رسالة جامعية
المؤلفون: Freis, Patricia
مرشدي الرسالة: Lyon, Ferraro-Peyret, Carole
مصطلحات موضوعية: NNE GEP, Tumeurs neuroendocrines, Stress du réticulum endoplasmique, UPR, Inhibiteurs de mTOR, GEP NEN, Neuroendocrine tumors, Endoplasmic reticulum stress, MTOR inhibitors, 616.99
الوصف: Les néoplasmes neuroendocrines gastro-entéro-pancréatiques (NNE GEP) représentent un groupe de tumeurs rares se développant à partir des cellules neuroendocrines de l'organisme. L'arsenal thérapeutique disponible aujourd'hui pour les NNE GEP reste faible, même s'il s'est étoffé au cours de ces dix dernières années avec l'arrivée des thérapies ciblées (inhibiteurs de mTOR et de tyrosine-kinase). Cependant, ces traitements présentent des résistances qui conditionnent leur efficacité et aucun biomarqueur permettant de sélectionner les patients répondeurs à ces traitements ou d'anticiper le développement de résistances n'est connu. Identifier de nouvelles cibles thérapeutiques et comprendre les mécanismes de résistance est donc un enjeu dans le traitement des NNE GEP. Nos travaux montrent que les cellules de NNE GEP soumises à l'hypoxie ou la déplétion en glucose activent l'Unfolded Protein Response (UPR) et que la voie PERK favorise la survie cellulaire. De plus, la modulation de la réponse UPR (via des inhibiteurs ou inducteurs de l'UPR) diminue la croissance tumorale dans un modèle murin de dissémination métastatique de NNE GEP. Nous avons également découvert qu'un inhibiteur de mTOR, la rapamycine, permet d'activer préférentiellement la voie PERK de l'UPR, favorisant la survie des cellules traitées par la rapamycine. Ces résultats montrent l'intérêt de cibler la réponse UPR dans le traitement des NNE GEP. De plus, nous suggérons la mise en place d'un mécanisme de résistance aux inhibiteurs de mTOR impliquant la voie PERK. Si ces résultats se confirment in vivo et ex vivo, l'association d'un inhibiteur de mTOR et d'un inhibiteur de PERK pourrait palier aux phénomènes de résistance rencontrés avec les inhibiteurs de mTOR dans les NNE GEP
Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) are defined as rare neoplastic lesions developing from neuroendocrine cells. Therapeutic options available for GEP NEN are scarce, although targeted therapies such as mTOR or tyrosine-kinase inhibitors provide new opportunities. However, tumor cells develop resistances to these treatments, which reduce their effectiveness. To date, no biomarker is available to select patients responding to these treatments or to anticipate the development of resistances. Identifying new therapeutic targets and understanding mechanisms of resistance are therefore a relevant issue in the treatment of GEP NEN.We found that GEP NEN cells induce the Unfolded Protein Response (UPR) when subjected to hypoxia or glucose depletion, and that PERK pathway promotes cell survival. Modulation of the UPR thanks to UPR inhibitors or inducers decreases tumor growth in a murine model of metastatic dissemination of GEP NEN. Moreover, the mTOR inhibitor rapamycin preferentially induces PERK arm of the UPR, thereby promoting survival of rapamycin-treated cells. These results show the interest in targeting the UPR in the treatment of NNE GEP. In addition, we here suggest a new resistance mechanism to mTOR inhibitors involving PERK pathway. If these results are confirmed in vivo and ex vivo, the combination of mTOR inhibitor and PERK inhibitor could overcome mTOR inhibitors resistances in GEP NEN -
3رسالة جامعية
المؤلفون: Gustafson, Heather Lynn
مرشدي الرسالة: Briehl, Margaret M., Rimsza, Lisa, Futscher, Bernard, Doetschman, Thomas, Lau, Serrine
مصطلحات موضوعية: Oxidative Stress, Cancer Biology, Mantle Cell Lymphoma, mTOR inhibitors
الوصف: Existing treatments for mantle cell lymphoma (MCL) are non-curative, demonstrating a need for a refined treatment approach. Recent clinical trials have shown promising results with the use of mammalian target of rapamycin inhibitors. I hypothesize that the anti-tumor effect of mTOR inhibitors in mantle cell lymphoma is mediated by an increase in manganese superoxide dismutase (MnSOD) protein expression and accumulation of hydrogen peroxide (H₂O₂). Findings indicate that the rapamycin-induced cytostatic effect is characterized by increased levels of MnSOD and H₂O₂, and is necessary for the full growth inhibitory effect of rapamycin. Furthermore, over-expression of MnSOD elevated the level of H₂O₂ and increased sensitivity to MnSOD. Treatment with rapamycin resulted in a loss of serine 473 phosphorylation of AKT and increased levels of MnSOD were found to be due to inhibition of the mTORC2 complex. These results are the first to suggest that long term treatment of MCL cells with rapamycin inhibits the mTORC2 complex. By understanding the key signaling molecules and affected pathways in the anti-tumor effects of mTOR inhibitors, we may be able to identify additional predictive markers to improve the therapeutic value, or study drug combinations that will enhance the effect of ROSinduced cytotoxicity. A retrospective study utilizing samples from lymphoma patients receiving standard anthracycline-based therapies, identified single nucleotide polymorphisms in oxidative stressrelated genes associated with survival. Individuals carrying minor allele SNPs in myeloperoxidase (MPO) and an aldo-keto reductase (AKR1C3) were found to be associated with shorter time to disease progression and death. This data suggest that some patients may benefit from a different therapy than the current standard of care and that regulation of the redox environment plays a role in aggressive lymphoma treatment response.
-
4مورد إلكتروني
المؤلفون: Glaviano, Antonino
المصدر: Molecular Cancer; vol 22, iss 1
مستخلص: The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed.
مصطلحات الفهرس: AKT inhibitors, ATP-competitive mTOR inhibitors, Allosteric mTOR inhibitors, Bi-steric mTOR inhibitors, Cancer, Dual PI3K/mTOR inhibitors, Isoform-specific PI3K inhibitors, PDK1 inhibitors, PI3K/AKT/mTORC pathway, Pan PI3K inhibitors, Humans, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, TOR Serine-Threonine Kinases, Neoplasms, article
-
5مورد إلكتروني
المصدر: Kimmel Cancer Center Faculty Papers
مستخلص: BACKGROUND: Malignant perivascular epithelioid cell tumors (PEComas) are exceedingly rare malignant mesenchymal neoplasms with characteristic morphological and immunohistochemical (IHC) patterns. However, some malignant PEComas are poorly differentiated with atypical histopathological features, making a definitive diagnosis difficult. PEComas are most commonly found in females and often show either TSC1 or TSC2 alterations, which result in the activation of the mTOR pathway, or TFE3 fusions. Given these molecular characteristics, mTOR inhibitors have recently been approved by the FDA in the treatment of malignant PEComas, particularly in those with TSC1/2 alterations. Therefore, molecular analyses may be helpful for both the diagnostic workup of and predicting response to mTOR inhibitors in cases of malignant PEComas. CASE PRESENTATION: Here, we report a case of an aggressive, 23 cm mesenteric malignant PEComa with multiple peritoneal metastases in a young male patient. Pathological examination of the initial biopsy showed a malignant epithelioid neoplasm with high-grade morphology and atypical immunoprofile, which precluded a definitive diagnosis. Because of the patient's excessive transfusion requirements due to intra-tumoral hemorrhage, a palliative R2 resection was performed. Histopathological examination of the tumor revealed focal immunoreactivity for Melan-A, HMB-45, desmin, and CD117. Although a diagnosis of malignant PEComa was favored, other entities such as epithelioid gastrointestinal stromal tumor (GIST) or melanoma could not be definitively ruled out. Given the favored diagnosis, the patient was started on sirolimus, an mTOR inhibitor, rather than chemotherapy. Molecular analyses were performed and the tumor was found to harbor mutations in TP53 and TSC2, supporting a definitive diagnosis of malignant PEComa. The patient was then switched to nab-sirolimus, with initial stabilization of the disease. CONCLUSIONS: This report details a multidisciplinary a
مصطلحات الفهرس: humans, male, MTOR inhibitors, mutation, perivascular epithelioid cell neoplasms, sarcoma, sirolimus, TOR serine-threonine kinases, Humans, Male, MTOR Inhibitors, Mutation, Perivascular Epithelioid Cell Neoplasms, Sarcoma, Sirolimus, TOR Serine-Threonine Kinases, Genomics, Medical Pathology, Oncology, Surgery, report
-
6مورد إلكتروني
مستخلص: Liver metastasis is the most fatal event of colon cancer patients. Warburg effect has been long challenged by the fact of upregulated oxidative phosphorylation (OXPHOS), while its mechanism remains unclear. Here, metastasis-associated antigen 1 (MTA1) is identified as a newly identified adenosine triphosphate (ATP) synthase modulator by interacting with ATP synthase F1 subunit alpha (ATP5A), facilitates colon cancer liver metastasis by driving mitochondrial bioenergetic metabolism reprogramming, enhancing OXPHOS; therefore, modulating ATP synthase activity and downstream mTOR pathways. High-throughput screening of an anticancer drug shows MTA1 knockout increases the sensitivity of colon cancer to mitochondrial bioenergetic metabolism-targeted drugs and mTOR inhibitors. Inhibiting ATP5A enhances the sensitivity of liver-metastasized colon cancer to sirolimus in an MTA1-dependent manner. The therapeutic effects are verified in xenograft models and clinical cases. This research identifies a new modulator of mitochondrial bioenergetic reprogramming in cancer metastasis and reveals a new mechanism on upregulating mitochondrial OXPHOS as the reversal of Warburg effect in cancer metastasis is orchestrated.
مصطلحات الفهرس: Adenosine triphosphate (ATP), Colorectal cancer, Mitochondrial glucose metabolism, Metastasis-associated antigen 1 (MTA1), MTOR inhibitors, Article
URL:
https://repository.hkust.edu.hk/ir/Record/1783.1-128241Test https://doi.org/10.1002/advs.202300756Test http://lbdiscover.ust.hk/uresolver?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/HKUST:SPI&rft.genre=article&rft.issn=2198-3844&rft.volume=&rft.issue=&rft.date=2023&rft.spage=&rft.aulast=Wang&rft.aufirst=&rft.atitle=MTA1%2C+a+Novel+ATP+Synthase+Complex+Modulator%2C+Enhances+Colon+Cancer+Liver+Metastasis+by+Driving+Mitochondrial+Metabolism+Reprogramming&rft.title=ADVANCED+SCIENCETest http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=LinksAMR&SrcApp=PARTNER_APP&DestLinkType=FullRecord&DestApp=WOS&KeyUT=001027203300001Test http://www.scopus.com/record/display.url?eid=2-s2.0-85164700632&origin=inwardTest -
7مورد إلكتروني
مستخلص: Even though Everolimus has been investigated in a phase II randomized trial as a host-directed therapy (HDT) to treat tuberculosis (TB), an oncological patient treated with Everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice and a non-tuberculous mycobacterial (NTM) infection in a year and a half time span. To investigate this interesting case, we isolated and genotypically characterized the Mycobacterium tuberculosis (Mtb) clinical strain from the patient and tested the effect of Everolimus on its viability in an axenic culture and in a peripheral blood mononuclear cell (PBMCs) infection model. To exclude strain-specific resistance, we tested the activity of Everolimus against Mtb strains of ancient and modern lineages. Furthermore, we investigated the Everolimus effect on ROS production and autophagy modulation during Mtb infection. Everolimus did not have a direct effect on mycobacteria viability and a negligible effect during Mtb infection in host cells, although it stimulated autophagy and ROS production. Despite being a biologically plausible HDT against TB, Everolimus does not exert a direct or indirect activity on Mtb. This case underlines the need for a careful approach to drug repurposing and implementation and the importance of pre-clinical experimental studies.
مصطلحات الفهرس: Everolimus, host-directed therapies, latent tuberculosis infection, mTOR inhibitors, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, info:eu-repo/semantics/article
URL:
https://hdl.handle.net/10807/232291Test
info:eu-repo/semantics/altIdentifier/pmid/36671372
info:eu-repo/semantics/altIdentifier/wos/WOS:000916728100001
volume:12
issue:1
firstpage:171
lastpage:N/A
issueyear:2023
journal:ANTIBIOTICS -
8مورد إلكتروني
المؤلفون: Rajdev, Lakshmi
المصدر: Investigational new drugs; vol 40, iss 6, 1306-1314; 0167-6997
مستخلص: This was a two-stage phase II trial of a mTORC1/2 inhibitor (mTORC: mammalian target of rapamycin complex) Sapanisertib (TAK228) in patients with rapalog-resistant pancreatic neuroendocrine tumors (PNETs) (NCT02893930). Approved rapalogs such as everolimus inhibit mTORC1 and have limited clinical activity, possibly due to compensatory feedback loops. Sapanisertib addresses the potential for incomplete inhibition of the mTOR pathway through targeting of both mTORC1 and mTORC2, and thus to reverse resistance to earlier rapamycin analogues. In stage 1, patients received sapanisertib 3 mg by mouth once daily on a continuous dosing schedule in 28-day cycle. This trial adopted a two-stage design with the primary objective of evaluating objective tumor response. The first stage would recruit 13 patients in order to accrue 12 eligible and treated patients. If among the 12 eligible patients at least 1 patient had an objective response to therapy, the study would move to the second stage of accrual where 25 eligible and treated patients would be enrolled. This study activated on February 1, 2017, the required pre-determined number of patients (n = 13) had entered by November 5, 2018 for the first stage response evaluation. The accrual of this trial was formally terminated on December 27, 2019 as no response had been observed after the first stage accrual. Treatment-related grade 3 adverse events were reported in eight (61%) patients with hyperglycemia being the most frequent, in three patients (23%). Other toxicities noted in the trial included fatigue, rash diarrhea, nausea, and vomiting. The median PFS was 5.19 months (95% CI [3.84, 9.30]) and the median OS was 20.44 months (95% CI [5.65, 22.54]). Due to the lack of responses in Stage 1 of the study, the study did not proceed to stage 2. Thus the potential to reverse resistance was not evident.
مصطلحات الفهرس: Humans, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Pancreatic Neoplasms, Sirolimus, Protein Kinase Inhibitors, Mechanistic Target of Rapamycin Complex 1, MTOR Inhibitors, PNET, Sapanisertib, mTORC1/2 inhibitor, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, article
-
9مورد إلكتروني
المؤلفون: Khaddam, Sinan
المصدر: Journal of kidney cancer and VHL; vol 9, iss 1, 42-47; 2203-5826
مستخلص: Renal angiomyolipoma (rAML) occurs rarely sporadically but is commonly encountered in patients with tuberous sclerosis complex and lymphangioleiomyomatosis. rAML is a rare entity, not seen regularly in daily practice; however, is commonly encountered and diagnosed by clinicians who approach and treat kidney masses. Basic knowledge of this entity is necessary to recognize that despite being benign, these tumors can rarely cause deadly complications such as hemorrhage or severe renal dysfunction or may have malignant components associated with them.
-
10مورد إلكتروني
المؤلفون: Zhang, Ziyang
المصدر: Nature; vol 609, iss 7928, 822-828; 0028-0836
مستخلص: On-target-off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates1,2. In diseases of the central nervous system, drugs with brain-restricted pharmacology are highly desirable. Here we report a strategy to achieve inhibition of mammalian target of rapamycin (mTOR) while sparing mTOR activity elsewhere through the use of the brain-permeable mTOR inhibitor RapaLink-1 and the brain-impermeable FKBP12 ligand RapaBlock. We show that this drug combination mitigates the systemic effects of mTOR inhibitors but retains the efficacy of RapaLink-1 in glioblastoma xenografts. We further present a general method to design cell-permeable, FKBP12-dependent kinase inhibitors from known drug scaffolds. These inhibitors are sensitive to deactivation by RapaBlock, enabling the brain-restricted inhibition of their respective kinase targets.
مصطلحات الفهرس: Brain, Humans, Glioblastoma, Sirolimus, Tacrolimus Binding Protein 1A, Ligands, Drug Therapy, Combination, Xenograft Model Antitumor Assays, TOR Serine-Threonine Kinases, MTOR Inhibitors, Brain Cancer, Rare Diseases, Brain Disorders, Neurosciences, Orphan Drug, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Neurological, General Science & Technology, article